BMC Cancer 2008, 8:352 http://www.biomedcentral.com/1471-2407/8/352 6. Yamazaki Y, Morita T: Molecular and functional diversity of vas- cular endothelial growth factors. Molecular diversity 2006, 10(4):515-527. 7. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M: Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-mac- rophages in humans. Blood 2001, 97(3):785-791. 8. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature clinical practice 2006, 3(1):24-40. 9. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400. 10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al.: Bevaci- zumab plus irinotecan, fluorouracil, and leucovorin for met- astatic colorectal cancer. The New England journal of medicine 2004, 350(23):2335-2342. 11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilen- baum R, Johnson DH: Paclitaxel-carboplatin alone or with bev- acizumab for non-small-cell lung cancer. The New England journal of medicine 2006, 355(24):2542-2550. 12. Gill DS, Damle NK: Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol 2006, 17(6):653-658. 13. Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L: Antagonists to human and mouse vas- cular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chemistry & biology 2006, 13(5):549-556. 14. Parker MH, Chen Y, Danehy F, Dufu K, Ekstrom J, Getmanova E, Gokemeijer J, Xu L, Lipovsek D: Antibody mimics based on human fibronectin type three domain engineered for ther- mostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 2005, 18(9):435-444. 15. Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA: Combination of a mon- oclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006, 118(10):2639-2643. 16. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC: Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 1995, 202(4):325-332. 17. Brekken RA, Huang X, King SW, Thorpe PE: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998, 58(9):1952-1959. 18. Roskoski R Jr: Vascular endothelial growth factor (VEGF) sig- naling in tumor progression. Crit Rev Oncol Hematol 2007, 62(3):179-213. 19. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL: Vascular endothelial growth factor/KDR activated microvessel den- sity versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000, 60:3088-3095. 20. Folkman J: Angiogenesis: an organizing principle for drug dis- covery? Nat Rev Drug Discov 2007, 6(4):273-286. 21. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenk- ier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England journal of medicine 2007, 357(26):2666-2676. 22. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23(31):8033-8040. 23. Kindler DNHL, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A double blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcit- abine plus placebo (P) in patients (pts) with advanced pan- creatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B. Journal of Clinical Oncology 2007, 25(18S):4508. 24. Molckovsky A, Siu LL: First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. J Hematol Oncol 2008, 1(1):20. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/8/352/pre pub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 10 of 10 (page number not for citation purposes)